64 results
6-K
EX-99.1
LEGN
Legend Biotech Corp
13 May 24
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
7:01am
did not incur any cost of license and other revenue for the three months ended March 31, 2023.
Research and Development Expenses: Research … driven by continuous research and development activities in cilta-cel, including start up costs for clinical production in Belgium and continued
6-K
LEGN
Legend Biotech Corp
13 May 24
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
7:01am
Collaboration revenue
Other revenue
Total revenue
Operating expenses:
Collaboration cost of revenue
Cost of license and other revenue
Research and development … of license and other revenue for the three months ended March 31, 2023.
Research and Development Expenses
Research and development expenses
F-3ASR
LEGN
Legend Biotech Corp
19 Mar 24
Automatic shelf registration (foreign)
7:57am
may never achieve or maintain profitability.
Our limited operating history, which has focused on research and development, makes it difficult … or efficacy.
Potential failure to obtain or maintain regulatory approvals for our product candidates.
Our primary research and development efforts
6-K
EX-99.1
iieuc
11 Mar 24
Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights
7:52am
6-K
euj34ay7znp
20 Nov 23
Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights
6:02am
6-K
EX-99.1
1ehkkj
20 Nov 23
Legend Biotech Reports Third Quarter 2023 Results and Recent Highlights
6:02am
6-K
re4jdbv y3gh2np
15 Aug 23
Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights
6:10am
6-K
EX-99.1
hhjp4o12m16lrg68jmg
15 Aug 23
Legend Biotech Reports Second Quarter 2023 Results and Recent Highlights
6:10am
F-3ASR
tloteno2cgesljn
26 May 23
Automatic shelf registration (foreign)
9:01am
6-K
EX-99.1
roo8g
18 May 23
Legend Biotech Corporation 6-K
8:30am
424B5
0qqmhscpq i7yg
8 May 23
Prospectus supplement for primary offering
8:45am
6-K
EX-99.1
ex26xu0
14 Apr 23
Master Technology Transfer, Manufacturing and Clinical Supply Services Agreement for Bcma Car-t Product
8:30am
6-K
EX-99.1
j2y8vd9x
3 Apr 23
Legend Biotech 6-K
4:01pm
6-K
EX-99.1
jc6l5
30 Mar 23
Legend Biotech Corporation 6-K
4:01pm
CORRESP
rtmrvhiiue e81f3i3nd
30 Sep 22
Correspondence with SEC
12:00am
UPLOAD
x9u8elqowl2n9nx4x07b
2 Sep 22
Letter from SEC
12:00am
6-K
EX-99.1
0a7h0
5 Aug 22
Legend Biotech Corp. 6-K
8:30am